Rinvoq
Active substance: upadacitinib
TABLET, EXTENDED RELEASE · UPADACITINIB 45 mg/1
United StatesActive
Marketing holder: AbbVie Inc.
Verified 2026-10-09 · openFDA NDC
Analogues in other countries- Source: openFDA NDC
- Countries with the substance registered: 2
Composition
- UPADACITINIB · 45 mg/1
Analogues by country
Products with the same active substance registered in other countries.
| Country | Products |
|---|---|
| EU 1 |
|
Import and control
Control by country
- United Statesprescription only
Source: openFDA NDC · record 01a1208c-4643-7d9f-aa20-c5c1335311f6,01a1208d-f9f9-745c-8b99-dec3645de431,01a12093-3d9e-7d6a-a7e2-ecda25099ed2,01a1209c-c983-791b-9f6e-5d4259ea9f4c;count=4 · valid from 2026-10-09 · verified 2026-10-09
Registration
- Registration number
- 0074-1043
- Registration status
- Active
- Dispensing
- Prescription only
- Route
- ORAL
Sources
- product · openFDA NDC · 0074-1043 · Verified 2026-10-09 · open in source
- registration_status · openFDA NDC · 0074-1043 · Verified 2026-10-09 · open in source
- ingredients.0 · openFDA NDC · 0074-1043 · Verified 2026-10-09 · open in source